Literature DB >> 35933495

Unspliced XBP1 contributes to cholesterol biosynthesis and tumorigenesis by stabilizing SREBP2 in hepatocellular carcinoma.

Mankun Wei1,2, Uli Nurjanah1,2, Arin Herkilini1,2, Can Huang3, Yanjun Li1,2, Makoto Miyagishi4, Shourong Wu5,6,7, Vivi Kasim8,9,10.   

Abstract

Cholesterol biosynthesis plays a critical role in rapidly proliferating tumor cells. X-box binding protein 1 (XBP1), which was first characterized as a basic leucine zipper-type transcription factor, exists in an unspliced (XBP1-u) and spliced (XBP1-s) form. Recent studies showed that unspliced XBP1 (XBP1-u) has unique biological functions independent from XBP1-s and could promote tumorigenesis; however, whether it is involved in tumor metabolic reprogramming remains unknown. Herein, we found that XBP1-u promotes tumor growth by enhancing cholesterol biosynthesis in hepatocellular carcinoma (HCC) cells. Specifically, XBP1-u colocalizes with sterol regulatory element-binding protein 2 (SREBP2) and inhibits its ubiquitination/proteasomal degradation. The ensuing stabilization of SREBP2 activates the transcription of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), a rate-limiting enzyme in cholesterol biosynthesis. We subsequently show that the XBP1-u/SREBP2/HMGCR axis is crucial for enhancing cholesterol biosynthesis and lipid accumulation as well as tumorigenesis in HCC cells. Taken together, these findings reveal a novel function of XBP1-u in promoting tumorigenesis through increased cholesterol biosynthesis in hepatocarcinoma cells. Hence, XBP1-u might be a potential target for anti-tumor therapeutic strategies that focus on cholesterol metabolism in HCC.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cholesterol biosynthesis; SREBP2; Tumorigenesis; Unspliced XBP1 (XBP1-u); XBP1

Mesh:

Substances:

Year:  2022        PMID: 35933495     DOI: 10.1007/s00018-022-04504-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  49 in total

Review 1.  Nuclear orphan receptors control cholesterol catabolism.

Authors:  D W Russell
Journal:  Cell       Date:  1999-05-28       Impact factor: 41.582

Review 2.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 3.  Mechanisms for cellular cholesterol transport: defects and human disease.

Authors:  Elina Ikonen
Journal:  Physiol Rev       Date:  2006-10       Impact factor: 37.312

4.  Cholesterol metabolism and cancer: the good, the bad and the ugly.

Authors:  Sandrine Silvente-Poirot; Marc Poirot
Journal:  Curr Opin Pharmacol       Date:  2012-10-26       Impact factor: 5.547

Review 5.  Mechanisms and regulation of cholesterol homeostasis.

Authors:  Jie Luo; Hongyuan Yang; Bao-Liang Song
Journal:  Nat Rev Mol Cell Biol       Date:  2019-12-17       Impact factor: 94.444

6.  Dysregulation of the mevalonate pathway promotes transformation.

Authors:  James W Clendening; Aleks Pandyra; Paul C Boutros; Samah El Ghamrasni; Fereshteh Khosravi; Grace A Trentin; Anna Martirosyan; Anne Hakem; Razqallah Hakem; Igor Jurisica; Linda Z Penn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

Review 7.  Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities.

Authors:  Binlu Huang; Bao-Liang Song; Chenqi Xu
Journal:  Nat Metab       Date:  2020-02-10

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 9.  Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development.

Authors:  Franziska Baenke; Barrie Peck; Heike Miess; Almut Schulze
Journal:  Dis Model Mech       Date:  2013-11       Impact factor: 5.758

10.  Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation.

Authors:  Yanjun Li; Vivi Kasim; Xuesong Yan; Lang Li; Ian Timothy Sembiring Meliala; Can Huang; Zhuolin Li; Ke Lei; Guanbin Song; Xiaodong Zheng; Shourong Wu
Journal:  Theranostics       Date:  2019-10-14       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.